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Abstract
Hormones, including estrogen and progesterone, and their receptors play an important role in the development and
progression of ovarian carcinoma. Androgen, its receptor and coactivators have also been implicated in these processes.
p44/Mep50/WDR77 was identified as a subunit of the methylosome complex and lately characterized as a steroid receptor
coactivator that enhances androgen receptor as well as estrogen receptor-mediated transcriptional activity in a ligand-
dependent manner. We previously described distinct expression and function of p44 in prostate, testis, and breast cancers.
In this report, we examined the expression and function of p44 in ovarian cancer. In contrast to findings in prostate and
testicular cancer and similar to breast cancer, p44 shows strong cytoplasmic localization in morphologically normal ovarian
surface and fallopian tube epithelia, while nuclear p44 is observed in invasive ovarian carcinoma. We observed that p44 can
serve as a coactivator of both androgen receptor (AR) and estrogen receptor (ER) in ovarian cells. Further, overexpression of
nuclear-localized p44 stimulates proliferation and invasion in ovarian cancer cells in the presence of estrogen or androgen.
These findings strongly suggest that p44 plays a role in mediating the effects of hormones during ovarian tumorigenesis.
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Introduction
Ovarian cancer is the fifth leading cause of death from cancer in
women, and the second most deadly gynecologic malignancy in
the United States [1]. Epithelial ovarian cancer accounts for about
3% of total cancer cases in women. National Cancer Institute
estimated that in 2010, 21,880 women would be diagnosed and
13,850 women would die of cancer of the ovary [2].
Ovarian cancer is a group of heterogeneous diseases and consists
of different histological types, which can be readily differentiated by
histological evaluation [3]. Current clinical guidelines set forth
by World Health Organization distinguish eight histological
tumor subtypes: papillary serous carcinoma (PSC), endometrioid
carcinoma (EMC), mucinous carcinoma (MUC), clear cell carci-
noma (CCC), transitional cell carcinoma (TCC), squamous cell,
mixed epithelial, and undifferentiated, with serous carcinoma
displaying the most malignant phenotype [4,5]. Genome-wide
global gene analysis further defines distinct expression profiles of
different types of ovarian cancer [6]. Different histological types of
ovarian cancer seem to be regulated by different pathogenic
pathways [7]. Most EMC and PSC present moderate to high levels
of ER [8,9,10] and AR expression [11,12].
Steroid hormone receptors, such as ER, progesterone receptor
(PR), and AR, are involved in the development of endocrine organ
cancers, including ovarian cancer [12,13,14]. Estrogens are known
to be regulators of growth and differentiation in normal ovaries, as
wellasinthedevelopmentof ovariancarcinoma, butthe mechanism
of this hormonal regulation remains ambiguous. Estrogen acts via
two nuclear receptors, estrogen receptor alpha (ERa) and estrogen
receptor beta(ERb) that bind toan estrogen responseelement (ERE)
in the promoter region of target genes, regulating their transcrip-
tional activity [15]. Similarly, AR is also a ligand-activated
transcriptional factor. The binding of androgen to the AR results
in nuclear localization of the hormone-receptor complex together
with coactivators and basal transcriptional machinery. Once in the
nucleus it then binds to an androgen response element (ARE),
regulating the expression of target genes [16].
AR is a prevalent sex steroid receptor expressed in ovarian
cancers. Eighty-four percent of tumors express AR, as opposed to
only 74% of tumors expressing ER and 41% expressing PR [17].
There is a higherriskof ovarian cancer inpost menopause, at which
time androgens are the primary steroids secreted by the ovary [18].
High expression of PR is associated with good prognosis in
multivariant analysis for ovarian cancer [19]. However, the results
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26250are controversial for the correlation of these three receptors with
prognosis and survival rate in patients [12,20].
p44 is a 44 kDa AR-interacting protein, which has been shown
to increase AR transcriptional activity. It contains 342 amino acid
residues and four putative WD40 repeats [21]. Furthermore, p44
exists in a methylsome complex with arginine methyl transferase 5
(PMRT5), and is also a subunit of the survival of motor neuron
(SMN) complex [22]. Due to phosphorylation of its subunit, the
SMN complex is active in the cytoplasm, where it promotes U
snRNP assembly [23]. The expression and function of p44 protein
have been reported in prostate, testicular, and breast cancers.
Interestingly, we observed distinct patterns of expression and
function in these reproductive organs [21,24,25]. We found
distinct intracellular localization of p44 in benign (as nuclear
protein) and malignant (as cytoplasmic protein) prostate tissue.
Nuclear expression of p44 inhibits prostate cancer growth under
the influence of androgen [21]. In contrast, p44 was expressed as a
cytoplasmic protein in benign breast epithelia and as a nuclear
protein in breast cancer. Nuclear p44 promoted breast cancer cell
growth in the presence of estrogen [21,24]. Our findings indicate
that p44 functions as a cofactor influencing the organ-specific
tumorigenesis in sex steroid hormone-regulated tumors.
In this study, we examined the expression of p44 in benign and
malignant human ovarian cells. We found that p44 was
differentially expressed in different types of ovarian cancers. In
endometrioid and serous ovarian cancers, p44 was expressed as a
nuclear protein. However, p44 was expressed as a cytoplasmic
protein in benign ovarian (OSE), fallopian tube (FT), and
endometrial (EM) epithelia. Our data also indicated that AR
and ER play a role in regulation of the nuclear-cytoplasmic
translocation of p44 in ovarian cancer and subsequently cancer
cell growth and invasion.
Results
Expression and cellular localization of AR coactivator p44
in human ovarian cancer: potential regulation of
localization by androgen and estrogen
To determine whether p44 is associated with ovarian cancers,
we examined p44 expression in benign ovary, endometrial, and
fallopian tube tissues and different histotypes of ovarian carcino-
mas by immunohistochemistry. To determine the cellular
localization of p44, the expression of p44 in cytoplasm and nuclei
were semi-quantitatively scored separately (see Materials and
Methods).
p44 was immunoreactive in both cytoplasm and nuclei. In
normal tissues, including FT, EM, and OSE, there was higher
level of p44 immunoreactive in cytoplasm than in nuclei
(cytoplasmic to nuclear ratio was approximately 2:1, Figure 1B).
In all 5 types of ovarian carcinomas, including MUC, CCC,
EMC, serous borderline (SBT), and PSC, there was an increase of
nuclear immunoreactivity for p44 in comparison to cytoplasm
(Figure 1A, Table 1), though nuclear p44 levels varied among
different histological types of ovarian cancer. SBT had the highest
immunoreactivity for p44 in nuclei and MUC had the lowest
(Figure 1B, S1). Multiple ANOVA analysis revealed that there
were significant differences of p44 immunoreactivity in nuclei
between benign (FT: 0.8960.17; EM: 0.5560.15; OSE:
0.5460.14) and malignant (CCC: 1.6460.13; EMC: 1.7160.16;
PSC: 2.0660.14; and SBT: 2.6760.17) epithelia (p,0.01). Paired
t-test revealed that there was significant difference of p44
immunoreactivity in nuclei pair-wise between FT and PSC,
OSE and PSC, EM and EMC, respectively (p,0.05). PSC, EMC,
and CCC carcinomas showed similar immunointensity of p44 in
nuclei by ANOVA analysis (p.0.05, Figure 1B, S1). In contrast,
there was minimal difference of cytoplasmic immunoreactivity for
p44 between each of benign and malignant epithelia (p.0.05,
Figure 1B). In general, EMC, PSC, and SBT had relatively
abundant ER expression and these tumors showed relatively
higher levels of p44 immunoreactivity in nuclei (Figure 1A, 1B,
Figure S1). The findings of difference in cellular localization of p44
between normal tissues and ovarian cancer may suggest a role of
p44 as an estrogen receptor mediator in tumorigenesis of ovarian
cancer.
To evaluate the relationship of p44 with AR and ER in ovarian
cancer, we first examined the expression levels of these receptors in
the selected ovarian cell lines. Western blot analysis revealed that
p44 expression was higher in ovarian cancer cell lines OVCAR-3
and SKOV-3 than the benign ovarian surface epithelial (OSE) cell
line T29. The levels of p44 expression positively correlated with
ERa/b and AR expression (Figure 1C). In particular, we found
that ERa expression was higher in SKOV-3 and conversely, ERb
isoform showed the highest levels in OVCAR-3 cells.To determine
p44 cellular localization and regulation by estrogen and androgen
in benign and malignant OSE cells, we examined the localization
of p44 under three different media conditions: hormone-free
medium and medium with defined levels of either androgen or
estrogen by immunofluorescence microscopy. As shown in
Figure 2, benign T29 cells had higher levels of cytoplasmic p44
and, to certain extent, nuclear p44 in all three media conditions. In
SKOV-3, p44 was localized predominantly in the nucleus in
hormone-free, androgen (10 nM synthetic androgen R1881) and
estrogen (10 nM 17b-estradiol) media (Figure 2). In OVCAR-3
cells, p44 was localized in both the nucleus and cytoplasm in
hormone-free media, and located to the nucleus in the presence of
either androgen or estrogen (Figure 2).
AR coactivator p44 functions as both AR and ER
coactivator in ovarian cells
p44 is a coactivator of AR and ER and has distinct expression in
prostate and breast cell lines [21,24]. To determine whether p44
functions as a transcription activator in ovarian cancer cell lines,
we performed an in vivo transcriptional assay using the dual
luciferase reporter system. We transiently transfected T29 cells
with vector expressing p44 and either a pair of vectors expressing
AR and a luciferase reporter under the control of four androgen
response elements (Figure 3A), or ERa, and a luciferase reporter
under the control of estrogen response elements (Figure 3B). In the
presence of androgen, p44 activated androgen receptor-driven
transcription in a dose-dependent manner, leading to as much as
2.6-fold increase of reporter activity compared to the control.
Similarly, in the presence of estrogen, p44 activated estrogen
receptor-dependent transcription in a dose-dependent manner: the
reporter signal increased as much as 4.5-fold compared to control.
When p44 was expressed alone, in the absence of either AR or
ER, no effect on reporter activity was observed, both in the
presence and absence of hormones in the media (data not shown),
confirming p44 activation via the hormone receptors. These
findings indicated that p44 indeed functions as a coactivator of
both androgen and estrogen receptors in ovarian cells.
AR coactivator p44 promotes ovarian cancer cell growth
and invasion
To dissect the effect of p44 on ovarian cancer cell proliferation,
we first transfected retroviral vectors expressing NLS-p44 into
SKOV-3 cells. NLS-p44 is constructed with nuclear localization
signal (NLS) fused in frame to N-terminus of p44. SKOV-3 cells
p44/Mep50 in Ovarian Cancer
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26250are unable to respond to estrogen activation [26,27]. After con-
firming that the transfected p44 was expressed, we proceeded to
analyze the proliferative status of the cells (Figure 4A). In both
hormone-free and estrogen-supplemented media, overexpression
of NLS-p44 had no effect on growth of SKOV-3 cells (p.0.05).
However, in the presence of androgen, the overexpression of NLS-
p44 led to approximately 33% reduction in cell growth (p,0.01).
Decreasing the levels of p44 by treating the SKOV-3 cells with the
corresponding siRNA led to similar results. While in media
containing androgen the knockdown of p44 led to ,25% decrease
of growth rate (p,0.05), and ,15% reduction of growth of the
cells in hormone-free media (p,0.05), there was no statistically
significant effect of siRNA treatment on the growth of cells in
medium containing estrogen (Figure 4C). Since the estrogen
receptor in SKOV-3 cells is non-responsive to estrogen, the results
validated our methods of the study.
Figure 1. p44 expression and cellular localization in ovarian cancer tissue and matched normal counterparts. A. Examples of p44
expression by immunohistochemistry in 4 different histological types of ovarian cancer and normal fallopian tube and endometrium (magnification
200x). B. Semiquantitative analysis of p44 immunointensity and its cellular localization in four different histological types of ovarian cancer and
normal fallopian tube and endometrium. Dark gray bars are nuclear p44 and light gray bars are cytoplasmic p44. Small t-bars represent standard
error. C. Western blot analysis of AR, ERa and ERb expression in different cell lines, including T29, SKOV-3, OVCAR-3. b-actin was used as a loading
control. The primary antibody dilution used for p44 was 1:5000, for AR 1:1000, for ERa and ERb 1:2000 and for b-actin 1:5000.
doi:10.1371/journal.pone.0026250.g001
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to estrogen stimulation [28]. Indeed, when OVCAR-3 cells were
growninmediasupplemented withestrogenorandrogen(Figure4B
and D, open triangles and squares), they both showed increased
proliferation compared to cells grown in hormone-free media (55%
and 40%, respectively). Contrary to the situation in SKOV-3 cells,
we observed a strong positive effect of nuclear p44 overexpression
on growth of OVCAR-3 cells in media supplemented wither either
androgen or estrogen. In the presence of androgen, the overex-
pression of NLS-p44 resulted in 1.5-fold increase in growth rate,
and in the presence of estrogen the observed growth induction was
1.6-fold. There was no significant influence of cell growth by p44
overexpression in hormone-free media (Figure 4B).
We also observed a strong, but negative, effect of depletion of
p44 in OVCAR-3 cells using siRNA confirmed at the protein
level by western blot analysis. While overexpression of p44 had no
significant influence on growth in hormone-free medium, knock-
down of p44 protein levels led to 25% reduction of growth rate in
the hormone-free medium. In hormone-supplemented media the
growth reduction associated with p44 depletion appeared even
stronger. In estrogen media, the p44 depletion caused 40%
reduction of tumor cell growth rate, while in the presence of
androgen this difference accounted for 33% (Figure 4D).
We further tested p44 effects on the cell invasion ability using an
in vitro Matrigel invasion assay. We observed increased invasiveness
of the cells in media supplemented with androgen as compared to
hormone-free medium. Treatment of cells with estrogen did not
change the number of cells crossing the membrane (Figure 5A).
When we overexpressed NLS-p44 in SKOV-3 cells, there was no
change in the ability of cells to invade through the Matrigel
membrane, eitherinhormone-freemedium ormediasupplemented
with androgen or estrogen. To block endogenous p44 expression,
we introduced p44 siRNA into SKOV-3 cells. In media lacking
hormones, the depletion of p44 did not affect tumor cell invasion
through Matrigel, as it did not affect tumor invasion in the estrogen-
containing media. In media supplemented with androgen, lack of
p44 expression significantly decreased cell invasion up to 3-fold
(Figure 5C).
We also tested the effect of p44 on invasion in OVCAR-3 cells.
Similar to SKOV-3 cells, increase or decrease of p44 expression did
not affect the cell invasion in hormone-free media (Figure 5B, D). In
androgen or estrogen-supplemented media, more than two fold
increase of Matrigel invasion was noted (Figure 5B). Consistently,
knockdown of p44 in OVCAR-3 cells resulted in a dramatic
reduction of invasion ability in the hormone-supplemented media.
Discussion
Steroid hormones are important factors in the development
and progression of ovarian cancer. The hormone receptors and
their cofactors are essential for hormone action. Most ovarian
carcinomas, including serous and endometrioid types, display
varied levels of ER, PR, and AR expression [12,27]. Expression of
sex steroid hormone receptors and their cofactors in ovarian
cancer provide the targets for anti-hormone treatments. Thus, it is
pivotal to characterize the role of sex hormones and their cofactor-
mediated tumorigenesis in ovarian cancer. It has been reported
that AR is an important marker in ovarian cancer [29], however,
the molecular mechanisms for AR associated aggressive ovarian
cancer behavior [30,31,32] are still poorly understood.
In our previous studies, we found that AR coactivator p44 plays an
important role in both prostate and breast cancers, indicating
involvement of the AR pathway in tumorigenesis of these endocrine
organs. In this study, we applied similar principles to determine the
contribution of p44 to oncogenic functions in ovarian cancer
tumorigenesis, in relation to androgen or estrogen. We found that
cytoplasmic p44 is highly expressed in benign ovarian, endometrial,
and fallopian tube surfaceepithelial cells. However, in different tumor
types, p44 has differential cellular expression patterns, reflected by
different levels of cytoplasmic and nuclear localizations. p44 is
significantly overexpressed in high-grade serous carcinoma, endome-
trioid carcinomas, clear cell carcinoma, and serous borderline tumors
(Figure 1A). In particular, nuclear p44 expression is significantly
higher in ovarian cancer tissues than in their matched benign
counterparts, supporting the functional role of nuclear p44 in
tumorigenesis of ovarian cancer. Similarly, western blot analysis
revealed comparable levels of p44 between OVCAR-3 and SKOV-3
(Figure 1C) when the cells were grown in complete medium
(with phenol red and non-charcoal stripped serum), however, in
androgen-supplemented medium, immunofluorescence staining re-
vealed that p44 is expressed at highest level in the nucleus (Figure 2).
It will be of great interest to determine in future studies whether the
levels of ER, AR and p44 expression are associated with specific
histologicaltypesofovarian cancer,tumorgrade,stages,and survival.
To further define the functional roles of p44, we investigated
p44 in benign and malignant OSE cell lines in the presence and
absence of androgen or estrogen. We used benign immortalized
ovarian surface epithelial cell line T29 and two malignant ovarian
cancer cell lines SKOV-3 and OVCAR-3 in this study. It was
reported that SKOV3 does not respond to estrogen while
OVCAR-3 cells are responsive to estrogen stimulation. In
agreement, we found that estrogen did not affect p44 localization,
cell proliferation, or invasion in SKOV-3 cells, while estrogen
enhanced p44 nuclear localization, cell proliferation, and invasion
in OVCAR-3 cells. While both ERa and ERb are expressed in
SKOV-3 cells (Figure 1C), SKOV-3 unresponsiveness to estrogen
Table 1. Summary of immunostaining results of p44 and
hormone receptors in different types of ovarian cancer and
normal control tissues.
No. of
Cases p44-N p44-C ER PR AR
PSC 32 Mean 2.06 1.84 0.73 0.88 0.21
Std. Error 0.14 0.14 0.20 0.20 0.11
EMC 34 Mean 1.71 1.58 1.92 1.09 0.15
Std. Error 0.16 0.10 0.24 0.20 0.09
CCC 15 Mean 1.64 1.51 1.06 0.52 0.00
Std. Error 0.13 0.14 0.38 0.25 0.00
MUC 15 Mean 0.92 0.38 0.00 0.00 0.00
Std. Error 0.14 0.14 0.00 0.00 0.00
SBT 9 Mean 2.67 1.22 1.59 1.51 0.30
Std. Error 0.17 0.22 0.48 0.34 0.28
FT 30 Mean 0.89 1.84 2.41 2.68 0.00
Std. Error 0.17 0.16 0.21 0.12 0.00
EM 20 Mean 0.55 1.67 1.87 2.28 0.00
Std. Error 0.15 0.14 0.39 0.36 0.00
OSE 28 Mean 0.54 1.08 0.35 0.48 0.25
Std. Error 0.14 0.18 0.16 0.16 0.12
Total 183 Mean 1.55 1.52 1.40 1.23 0.11
Std. Error 0.08 0.06 0.12 0.11 0.04
doi:10.1371/journal.pone.0026250.t001
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p44 may be mediated by ERa, instead of ERb.
p44 significantly enhanced malignant OSE cell proliferation
and invasion in the presence of androgen or estrogen, indicating
that expression of AR or ER are required for p44 to stimulate
mitogenesis and invasion (Figure 1C). p44-mediated tumorigenic
function seems to be different between prostate and ovarian
cancer. In prostate cancer, nuclear p44 inhibits cell proliferation in
an androgen-dependent manner. In the ovarian cancer cell line
OVCAR-3, nuclear p44 promotes cell growth. In particular, it is
noted that nuclear p44 promotes invasion in both androgen and
estrogen media. The results from ovarian cancer are similar to
what we observed in breast. In breast cancer, nuclear p44
promotes tumor cell proliferation in an estrogen-dependent
fashion [24]. Although our siRNA-mediated knockdown experi-
ments demonstrated that our p44 antibody specifically recognized
a single protein species in prostate, breast, and ovary, we can’t
completely exclude the possibility that highly related but
functionally distinct proteins (e.g. splicing variants of p44) act as
distinct hormone receptor cofactors in each of these tissues. With
this caveat, our findings suggest that p44 may also act through an
ER-mediated functional pathway in ovarian tissue.
Figure 2. Localization of p44 in T29, SKOV-3, and OVCAR-3 cell lines using immunoflorescence. p44 primary antibody and rhodamine-
conjugated rabbit polyclonal secondary antibody was used. DAPI was used to stain the nuclei. (Magnification: 400x)
doi:10.1371/journal.pone.0026250.g002
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ovarian cancer proliferation and invasion. These processes are
regulated by androgen and estrogen. p44 may be a potential target
for the treatment of ovarian cancer.
Materials and Methods
Case selection, TMA and IHC
The cases were collected after surgery at Northwestern
Memorial Hospital and New York University from 1996 to
2009. Approvals of Institutional Research Board (IRB) from both
institutions were obtained (exempt). A total of 105 cases of ovarian
cancer were collected for this study (Table 1). All PSC and EMC
cases were retrieved from the NYU tissue bank and all other types
of ovarian cancer, as well as normal control tissues, were retrieved
from the NWU tissue bank. This included histological diagnosis of
high-grade papillary serous carcinoma (PSC, N=32), serous
borderline tumor (SBT, N=9), endometrioid ovarian carcinoma
(EMC, N=34), mucinous ovarian carcinoma (MUC, N=15) and
clear cell ovarian carcinoma (CCC, N=15). Normal control
tissues used in this study included: 30 normal fallopian tubes (FT,
the closest normal controls for high grade serous carcinoma),
20 normal endometria (EM, the closest normal controls for
endometrioid carcinoma), and 28 normal ovaries (OSE, ovarian
surface epithelia, as general control tissue).
All carcinomas were ovarian primary. Tissue microarray (TMA)
preparation has been described in our previous study [33]. In
brief, 0.6 and 1 mm tissue cores were collected from each case of
well-preserved tumor sections and high density TMA were
prepared in two receipting blocks.
The production, affinity purification, and specificity of the
rabbit polyclonal p44 antibody used have been described
previously [34]. Preimmune serum was used as control. The
specificity of the p44 antibody was confirmed by an siRNA assay
that showed reduced p44 expression with p44 RNA interference
[21]. The relative levels of p44 expression were scored semi-
quantitatively by combination of immunointensity [0 (negative),
1+ (faint), 2+ (weak), 3+ (moderate), and 4+ (strong) expression]
and immunopercentage (1 as 0–10%, 2 as 10–50%, 3 as 50–75%
and 4 as 75–100%)]. Statistical analyses were performed by t-test.
Cell culture and cell proliferation assay
The cell lines SKOV-3 [35] and OVCAR-3 [28] were obtained
from the American Type Culture Collection. The benign
immortalized ovarian surface epithelial cell line T29 [36], as
previously described in detail, was maintained in medium 199 and
MCDB105 (Sigma). The two ovarian cancer cell lines SKOV-3
and OVCAR-3 were cultured in McCoy’s 5a medium (Invitrogen)
and RPMI 1640 (Gibco) respectively, supplemented with 10%
FBS and 1 U/ml of penicillin and 1 mg/ml streptomycin. To
measure the proliferation rate, 2610
4 cells were seeded into 6-well
plates. At the appropriate time points the cells were treated with
0.25% trypsin and 0.38 mg/ml EDTA (Gibco) and counted using
a hemocytometer (Reichert).
Western blot analysis
Western blot analysis was used to check p44, AR, ERa, and
ERb expression in complete medium, knockdown of p44, and
overexpression of p44 plasmids (pBabe vector and pBabeNLSp44)
in ovarian cell lines. The cells were either grown in 10 cm dishes, 6
well or 24 well plates. Lysis buffer containing protease cocktail
inhibitor (Sigma) in 1:100 ratio was added to the pellets for
resuspension. The protein concentration was measured using Bio-
Rad protein assay and appropriate amount of protein was loaded
for electrophoresis on the SDS-polyacrylamide gel electrophoresis
(SDS-PAGE). The protein was then transferred to nitrocellulose
membrane for western blot analysis. The membranes were
blocked for 1 hour in 5% nonfat dry milk in Tris buffered saline
and Tween 20 (20 mM Tris- HCl, pH 7.6, 150 mM NaCl, and
0.1% Tween 20). Blots were then incubated with antibodies raised
against AR, ERa,E R b (Santa Cruz Biotechnology), p44 and
b-actin for 2 hours at room temperature, washed with Tris-
buffered saline Tween 20 three times. After the washes, the blots
were incubated for 2 hrs with appropriate horseradish peroxidase-
conjugated secondary antibody (GE Healthcare). The protein
bands were detected by using enhanced chemiluminescence kit
(GE Healthcare).
Immunofluorescent microscopy
T29, SKOV-3, and OVCAR-3 cells were grown at two
densities- 3610
4 and 1610
4 per well for three different media
conditions (hormone-free, androgen, and estrogen) on chambered
slides. The cells were first rinsed three times in PBS, and fixed for
20 min with 4% paraformaldehyde in PBS at room temperature.
After fixation, the cells were permeablized with methanol and
acetone (1:1) and incubated at 220uC for 20 mins. The cells were
washed 3 times in PBS and blocked for 1 hour with a solution
of 5% BSA in TBS-T. The cells were then incubated with
p44 primary antibody (1:250) for 2 hours at room temperature.
Figure 3. p44 functions as an ERa and AR co-activator in
ovarian cell lines. A. Vectors containing p44 and AR were transfected
into T29 cells together with a reporter vector containing luciferase gene
under the control promoter containing 4 androgen response elements.
B. Vectors containing p44 and ERa were transfected into T29 cells
together with the ER-luc reporter vector. Reporter activity was expressed
as relative units.
doi:10.1371/journal.pone.0026250.g003
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PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26250Figure 4. The effect of knockdown and overexpression of p44 on growth of ovarian cancer cells. A,B: SKOV-3 cells (A) and OVCAR-3 cells
(B) were transfected either with pBabe-NLSp44 overexpression vector or a control vector, and cultured either in hormone-free medium or in the
presence of androgen or estrogen. The overexpression of p44 was verified by western blot (samples taken every other day) and cells were counted
every day. C,D: SKOV-3 cells (C) and OVCAR-3 cells (D) were treated with p44 siRNA using Hiperfect and cultured either in hormone-free medium or in
the presence of androgen or estrogen. The siRNA treatment was repeated every other day. The overexpression and knockdown of p44 was verified
by western blot (samples taken every other day) and cells were counted every day.
doi:10.1371/journal.pone.0026250.g004
p44/Mep50 in Ovarian Cancer
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with rhodamine-conjugated rabbit polyclonal antibody (1:500)
(Abcam) for 1 hour in the dark at room temperature. For counter
staining DAPI was applied (1:1000) and incubated at room
temperature for 5 mins in the dark. The intracellular localization
of p44 was then examined using Nikon Digital DXM1200 F
microscope with Nikon-ACT program.
RNA Interference assay
Three siRNAs most effective in reducing the level of p44 protein
in the ovarian cells were pooled in equimolar amounts and used in
subsequent experiments in general at concentration of 100 nM
(Table 2). Scrambled siRNA (Ambion) was used as a control.
Cells were grown in 6 well plates to desired confluency in 2 ml of
appropriate medium containing serum without antibiotics. 100 nM
of siRNA was diluted in 423 ml Opti-MEM media (Gibco) without
serum followed by 75 ml of HiPerfect reagent (Qiagen) and
incubated for 10 minutes at room temperature to allow formation
of transfection complexes. The cells were then incubated with the
transfection complexes under their normal conditions for 48 hours.
Electroporation
Three plasmids – pBabe vector, pBabeNLSp44 [21], and GFP
(control) – were transfected into cells using electroporation. The
cells were grown in three conditions – hormone-free, androgen
(10 nM), and estrogen (10 nM). The cells were grown to 80%
confluency. The pelleted cells were then resuspended in 100 mlo f
Nucleofactor solution (82 ml of solution +18 ml of supplement
solution) (Lonza) for each reaction. Four ng of plasmid was then
combined and cell/DNA suspension was transferred into
electroporation cuvette. Nucleofactor program recommended
for each cell line by the manufacturer was selected and applied.
After the electroporation the cuvette was removed and cells
immediately transferred to 10 ml of corresponding medium
with FCS and incubated for 48 hrs under normal growth
conditions.
Luciferase assay
In vivo reporter transcription assay was performed using the
Dual-reporter Luciferase Assay System (Promega) according to
manufacturer’s instructions. The light output was measured by
Lumat LB9507 luminometer (Berthold). The vectors pcDNA-fAR,
pcDNA-ERa, and the reporter vectors ER-luc and pGL3-ARE4
were acquired from Addgene.
Matrigel invasion assay
Cells were resuspended in the medium without serum at
1610
5/ml and 0.5 ml were loaded into the inserts of Biocoat
Figure 5. The effect of knockdown and overexpression of p44 on invasive ability of ovarian cancer cells. A,B: SKOV-3 cells (A) and
OVCAR-3 cells (B) were transfected either with pBabe-NLSp44 overexpression vector or a control vector; C,D: SKOV-3 cells (C) and OVCAR-3 cells (D)
were treated with p44 siRNA using Hiperfect and cultured either in the hormone-free medium or in the presence of androgen or estrogen. The
overexpression and knockdown of p44 was verified by western blot (see Figure 4). Cells were seeded onto Matrigel membranes in hormone-free
media. Androgen or estrogen were used as chemoatractants in the bottom chamber.
doi:10.1371/journal.pone.0026250.g005
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chambers were filled with 750 ml of the medium containing 10%
fetal bovine serum as the chemoattractant. After 24 h the inserts
were removed and the non-invading cells were cleared away from
the upper surface of the membrane using a cotton swab. The cells
that migrated to the lower surface of the membrane were stained
with Diff Quik stain and counted under a microscope.
Statistical analysis
The mean values and standard errors were calculated. For two-
group comparison, we used Student’s t-test and Mann-Whitney U-
test. For multiple-group comparison, we used ANOVA analysis.
The p values less than 0.05 (p,0.05) were considered statistically
significant.
Supporting Information
Figure S1 Expression of p44, ER, PR, and AR in ovarian
cancer tissue and matched normal tissues. A: Relative
expression (y axis) of ER, PR, AR, and nuclear and cytosolic p44
determined by semiquantitative analysis of immunointensity. The
analysis was performed in 4 different histological types of ovarian
cancer and normal fallopian tube and endometrium (x axis). Small
t-bars represent standard error of measurement. B: Dotplot analysis
in 105 ovarian cancer patients. Each dot represents one tumor
sample(yaxis)with relative expression ofthe selected geneproducts,
including p44N (nucleus), p44C (cytoplasm), ER, PR, and AR for
individual cases in panel A.
(TIF)
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